PI3K/Akt/mTOR-IN-2 NEW
| Price | $33 | $76 | $133 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-09 |
Product Details
| Product Name: PI3K/Akt/mTOR-IN-2 | CAS No.: 2757804-89-8 |
| Purity: 99.61% | Supply Ability: 10g |
| Release date: 2025/05/09 |
Product Introduction
Bioactivity
| Name | PI3K/Akt/mTOR-IN-2 |
| Description | PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor with anticancer effects and selectivity for MDA-MB-231 cells (IC50 2.29 μM). It induces cell cycle arrest and apoptosis in cancer cells. |
| In vitro | PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 h) demonstrates significant anti-cancer efficacy, with IC50 values between 2.29 and 24.63 μM, notably 2.29 μM in MDA-MB-231 cells.[1] It induces growth inhibition in MDA-MB-231 cells by causing cell cycle arrest at G0/G1 (1, 2, and 4 μM; 24 h), elicits dose- and time-dependent apoptosis (1, 2, and 4 μM; 24, 48, and 72 h), increases Bax expression and decreases Bcl-2 expression (1, 2, and 4 μM; 48 h), and triggers mitochondria-dependent apoptosis by disrupting mitochondrial membrane potential, increasing ROS, reducing GSH levels, and elevating intracellular Ca2+ (1, 2, and 4 μM; 24 h).[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (192.79 mM), Sonication is recommended. |
| Keywords | PI3K | mTOR | Apoptosis | Akt |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Metronidazole | Tributyrin | L-Ascorbic acid sodium salt | Salicylic acid | Alginic acid |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | PI3K-AKT-mTOR Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Hematonosis Compound Library | Anti-Obesity Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-04-30 | |
| $53.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-05-09 | |
| $0.00/1g |
VIP1Y
|
Wuhan Circle Star Chem-medical Technology Co.,Ltd
|
2025-01-17 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY